Insider Selling: Tyra Biosciences, Inc. (NASDAQ:TYRA) CEO Sells 10,035 Shares of Stock

Tyra Biosciences, Inc. (NASDAQ:TYRA) CEO Todd Harris sold 10,035 shares of the firm’s stock in a transaction dated Tuesday, October 15th. The stock was sold at an average price of $24.31, for a total value of $243,950.85. Following the completion of the sale, the chief executive officer now directly owns 1,467,338 shares in the company, valued at approximately $35,670,986.78. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.

Todd Harris also recently made the following trade(s):

• On Thursday, October 17th, Todd Harris sold 15,394 shares of Tyra Biosciences stock. The stock was sold at an average price of $25.85, for a total transaction of $397,934.90.
• On Monday, September 30th, Todd Harris sold 500 shares of Tyra Biosciences stock. The stock was sold at an average price of $24.00, for a total value of $12,000.00.
• On Wednesday, September 25th, Todd Harris sold 600 shares of Tyra Biosciences stock. The stock was sold at an average price of $24.01, for a total value of $14,406.00.
• On Monday, September 23rd, Todd Harris sold 10,092 shares of Tyra Biosciences stock. The shares were sold at an average price of $24.13, for a total transaction of $243,519.96.
• On Thursday, September 19th, Todd Harris sold 5,698 shares of Tyra Biosciences stock. The stock was sold at an average price of $24.31, for a total transaction of $138,518.38.

Tyra Biosciences Stock Up 0.3 %

Shares of TYRA traded up $0.08 during trading on Thursday, reaching $25.98. The company’s stock had a trading volume of 176,569 shares, compared to its average volume of 150,106. Tyra Biosciences, Inc. has a twelve month low of $10.38 and a twelve month high of $27.17. The company has a market cap of $1.37 billion, a price-to-earnings ratio of -15.37 and a beta of 1.01. The company has a fifty day moving average of $22.06 and a two-hundred day moving average of $19.37.

Tyra Biosciences (NASDAQ:TYRA) last posted its quarterly earnings data on Wednesday, August 7th. The company reported ($0.32) EPS for the quarter, beating analysts’ consensus estimates of ($0.41) by $0.09. As a group, equities analysts forecast that Tyra Biosciences, Inc. will post -1.53 EPS for the current fiscal year.

Institutional Investors Weigh In On Tyra Biosciences

Several institutional investors and hedge funds have recently made changes to their positions in the company. HighVista Strategies LLC acquired a new stake in Tyra Biosciences during the second quarter worth about $257,000. SG Americas Securities LLC bought a new position in shares of Tyra Biosciences during the third quarter valued at approximately $311,000. Rhumbline Advisers raised its position in shares of Tyra Biosciences by 12.3% during the 2nd quarter. Rhumbline Advisers now owns 23,572 shares of the company’s stock worth $377,000 after purchasing an additional 2,574 shares during the period. Bank of New York Mellon Corp lifted its holdings in shares of Tyra Biosciences by 32.8% in the 2nd quarter. Bank of New York Mellon Corp now owns 58,087 shares of the company’s stock worth $929,000 after purchasing an additional 14,352 shares during the last quarter. Finally, Oppenheimer & Co. Inc. acquired a new position in Tyra Biosciences during the 1st quarter valued at approximately $977,000. 84.14% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research firms have commented on TYRA. Wedbush reissued an “outperform” rating and issued a $28.00 price objective on shares of Tyra Biosciences in a research report on Thursday, August 8th. Piper Sandler started coverage on Tyra Biosciences in a research note on Thursday, August 15th. They issued an “overweight” rating and a $33.00 target price for the company. Oppenheimer boosted their price target on Tyra Biosciences from $25.00 to $33.00 and gave the stock an “outperform” rating in a research report on Thursday, September 19th. Finally, HC Wainwright upped their price target on Tyra Biosciences from $25.00 to $30.00 and gave the stock a “buy” rating in a report on Monday, October 7th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat.com, Tyra Biosciences currently has a consensus rating of “Moderate Buy” and a consensus target price of $27.80.

About Tyra Biosciences

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.